Treatment selection for adenomyosis based on imaging findings and patient characteristics

Treatment selection for adenomyosis based on imaging findings and patient characteristics Corresponding Author Hiroshi Kobayashi Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Japan Department of Gynecology and Reproductive Medicine, Ms.Clinic MayOne, Kashihara, Japan Correspondence Hiroshi Kobayashi, Department of Obstetrics and Gynecology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Japan. Email: [email protected] Search for more papers by this authorCorresponding Author Hiroshi Kobayashi Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Japan Department of Gynecology and Reproductive Medicine, Ms.Clinic MayOne, Kashihara, Japan Correspondence Hiroshi Kobayashi, Department of Obstetrics and Gynecology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Japan. Email: [email protected] Search for more papers by this authorAbstract Adenomyosis is an estrogen-dependent disorder characterized by substantial heterogeneity in lesion distribution, symptom presentation, disease severity, and reproductive impact, which limits the effectiveness of uniform treatment strategies. To summarize recent evidence on pharmacological and minimally invasive treatments for adenomyosis and to propose a clinically practical framework for treatment selection based on magnetic resonance imaging (MRI)-based lesion subtypes, symptom phenotypes, disease severity, and reproductive intentions. A narrative review of recent literature was conducted focusing on hormonal therapies, gonadotropin-releasing hormone (GnRH) antagonists, the levonorgestrel-releasing intrauterine system (LNG-IUS), dienogest, and minimally invasive treatments such as high-intensity focused ultrasound (HIFU) and endometrial ablation. Outcomes were evaluated in relation to MRI-based lesion localization, predominant symptoms, uterine size, and fertility preservation goals. Pharmacological therapy remains the cornerstone of conservative management. Sequential strategies using short-term GnRH antagonists followed by maintenance therapy have been explored, although robust evidence is limited. LNG-IUS and dienogest are commonly selected according to bleeding- or pain-dominant symptoms and MRI-based lesion subtypes, but interindividual variability in treatment response persists. Minimally invasive treatments show favorable outcomes mainly in localized disease, whereas efficacy in diffuse adenomyosis remains inconsistent. Treatment strategies differ according to reproductive intentions, with time-limited interventions being central in fertility-preserving management. Treatment of adenomyosis should move beyond a uniform approach toward individualized strategies integrating imaging findings and patient characteristics. An MRI-based framework may support more rational and effective clinical decision making. CONFLICT OF INTEREST STATEMENT The author declare no conflicts of interest. DATA AVAILABILITY STATEMENT Data sharing is not applicable to this article as no new data were created or analyzed in this study. Supporting Information | Filename | Description | |---|---| | ijgo70992-sup-0001-Tables.docxWord 2007 document , 37.1 KB | Table S1. Main characteristics of studies related to LEP. Table S2. Main characteristics of studies related to GnRH antagonists. Table S3. Main characteristics of studies related to dienogest. Table S4. Key characteristics of studies related to LNG-IUS. Table S5. Key characteristics of studies related to minimally invasive and multidisciplinary treatment strategies. | Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES - 1Martire FG, Costantini E, D'Abate C, et al. Endometriosis and Adenomyosis: from pathogenesis to follow-up. Curr Issues Mol Biol. 2025; 47(5):298. doi:10.3390/cimb47050298 - 2Kobayashi H, Imanaka S. Proposal for developing treatment algorithms of women with symptomatic adenomyosis: a single-center experience. J Obstet Gynaecol Res. 2021; 47(9): 3257-3268. doi:10.1111/jog.14904 - 3Agostinho L, Cruz R, Osório F, Alves J, Setúbal A, Guerra A. MRI for adenomyosis: a pictorial review. Insights Imaging. 2017; 8(6): 549-556. doi:10.1007/s13244-017-0576-z - 4Yavuz O, Akdöner A, Özgozen ME, et al. Prediction of adenomyosis according to revised definitions of morphological uterus sonographic assessment features. Front Med. 2024; 11:1387515. doi:10.3389/fmed.2024.1387515 10.3389/fmed.2024.1387515Google Scholar - 5Sinha S, Agarwal M, Bhadani PP, Roy R, Sinha U. Development and validation of sonological classification and scoring system for uterine adenomyosis: a pilot study. F1000Res. 2023; 11:1138. doi:10.12688/f1000research.125700.2 - 6Valdés-Bango M, Ros C, Daza M, et al. Internal and external adenomyosis phenotypes: ultrasound features and association with clinical outcomes. Hum Reprod. 2024; 30(7): 1471-1480. doi:10.1093/humrep/deae105 10.1093/humrep/deae105Google Scholar - 7Kobayashi H, Matsubara S. A classification proposal for Adenomyosis based on magnetic resonance imaging. Gynecol Obstet Investig. 2020; 85(2): 118-126. doi:10.1159/000505690 - 8Tang Y, Jiang ZJ, Wen MB, et al. Magnetic resonance imaging-based classifications for symptom of Adenomyosis. Gynecol Obstet Investig. 2024; 89(5): 402-412. doi:10.1159/000535802 - 9Stratopoulou CA, Donnez J, Dolmans MM. Conservative Management of Uterine Adenomyosis: medical vs. surgical approach. J Clin Med. 2021; 10(21):4878. doi:10.3390/jcm10214878 - 10Ioannidou A, Louis K, Sioutis D, Panagopoulos P, Theofanakis C, Machairiotis N. Conservative surgical Management of Adenomyosis: implications for infertility and pregnancy outcomes-a perspective review. J Clin Med. 2025; 14(19):6956. doi:10.3390/jcm14196956 - 11Habiba M, Guo SW, Benagiano G. Adenomyosis and abnormal uterine bleeding: review of the evidence. Biomolecules. 2024; 14(6):616. doi:10.3390/biom14060616 - 12Etrusco A, Barra F, Chiantera V, et al. Current medical therapy for Adenomyosis: from bench to bedside. Drugs. 2023; 83(17): 1595-1611. doi:10.1007/s40265-023-01957-7 - 13Shaaban OM, Ali MK, Sabra AM, Abd El Aal DE. Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial. Contraception. 2015; 92(4): 301-307. doi:10.1016/j.contraception.2015.05.015 - 14Hassanin AI, Youssef AA, Yousef AM, Ali MK. Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: a randomized clinical trial. Int J Gynaecol Obstet. 2021; 154(2): 263-269. doi:10.1002/ijgo.13600 - 15Carrillo Torres P, Martínez-Zamora MÁ, Ros C, et al. Clinical and sonographic impact of oral contraception in patients with deep endometriosis and adenomyosis at 2 years of follow-up. Sci Rep. 2023; 13(1): 2066. doi:10.1038/s41598-023-29227-2 - 16Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J. Combined Oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk. Front Endocrinol (Lausanne). 2021; 12:769187. doi:10.3389/fendo.2021.769187 - 17Cope AG, Ainsworth AJ, Stewart EA. Current and future medical therapies for Adenomyosis. Semin Reprod Med. 2020; 38(2–03): 151-156. doi:10.1055/s-0040-1719016 - 18Barretta M, Vignali M, La Marca A, Grandi G. The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications. Expert Opin Drug Metab Toxicol. 2024; 17: 1-13. doi:10.1080/17425255.2024.2441981 10.1080/17425255.2024.2441981Google Scholar - 19Donnez J, Donnez O, Brethous M, et al. Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study. Reprod Biomed Online. 2022; 44(1): 200-203. doi:10.1016/j.rbmo.2021.09.019 - 20Stewart EA, Lukes AS, Venturella R, et al. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials. Am J Obstet Gynecol. 2023; 228(3): 320.e1-320.e11. doi:10.1016/j.ajog.2022.11.1278 - 21Catherino WH, Al-Hendy A, Zaim S, et al. Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2. Fertil Steril. 2025; 124(3): 523-533. doi:10.1016/j.fertnstert.2025.04.037 - 22Nishida H, Takehara K, Onodera T, et al. Sequential therapy of dienogest following relugolix for adenomyosis and impact on symptoms and serum CA125 levels: a case series. BMC Womens Health. 2025; 25(1): 150. doi:10.1186/s12905-025-03681-8 - 23Donnez J, Donnez O, Tourniaire J, et al. Uterine Adenomyosis treated by Linzagolix, an Oral gonadotropin-releasing hormone receptor antagonist: a pilot study with a new ‘hit hard first and then maintain’ regimen of administration. J Clin Med. 2021; 10(24):5794. doi:10.3390/jcm10245794 - 24Galati G, Ruggiero G, Grobberio A, et al. The role of different medical therapies in the Management of Adenomyosis: a systematic review and meta-analysis. J Clin Med. 2024; 13(11):3302. doi:10.3390/jcm13113302 - 25Selntigia A, Molinaro P, Tartaglia S, Pellicer A, Galliano D, Cozzolino M. Adenomyosis: an update concerning diagnosis, treatment, and fertility. J Clin Med. 2024; 13(17):5224. doi:10.3390/jcm13175224 - 26Donnez O, Donnez J. Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis. Fertil Steril. 2020; 114(3): 640-645. doi:10.1016/j.fertnstert.2020.04.017 - 27Shi J, Gu Z, Wu Y, et al. Long-term efficacy and safety of levonorgestrel releasing intrauterine system in the treatment of adenomyosis: evidence mapping. Arch Gynecol Obstet. 2024; 310(1): 55-67. doi:10.1007/s00404-024-07546-7 - 28Fawzy M, Mesbah Y. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial. Arch Gynecol Obstet. 2015; 292(6): 1267-1271. doi:10.1007/s00404-015-3755-5 - 29Hirata T, Izumi G, Takamura M, et al. Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study. Gynecol Endocrinol. 2014; 30(10): 726-729. doi:10.3109/09513590.2014.926882 - 30Kobayashi H. Efficacy, adverse events, and challenges of Dienogest in the Management of Symptomatic Adenomyosis: a comparison with different hormonal treatments. Gynecol Obstet Investig. 2023; 88(2): 71-80. doi:10.1159/000529185 - 31Ali MK, Hussein RS, Abdallah KS, Mohamed AA. The use of dienogest in treatment of symptomatic adenomyosis: a systematic review and meta-analysis. J Gynecol Obstet Hum Reprod. 2024; 53(7):102795. doi:10.1016/j.jogoh.2024.102795 - 32Vannuccini S, La Torre F, Toscano F, et al. Medical treatment for adenomyosis: long term use of progestins. Gynecol Endocrinol. 2025; 41(1):2511329. doi:10.1080/09513590.2025.2511329 - 33Shen M, Liu X, Ding D, Guo SW. Results of dienogest treatment and its discontinuation in patients with symptomatic adenomyosis: a prospective cohort study. Reprod Biomed Online. 2025; 51(2):104880. doi:10.1016/j.rbmo.2025.104880 - 34Matsushima T, Akira S, Yoneyama K, Takeshita T. Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest. Gynecol Endocrinol. 2020; 36(6): 521-524. doi:10.1080/09513590.2019.1683818 - 35Han X, Gao X, Wang F, Shang C, Liu Z, Guo H. Heterogeneity of clinical symptoms and therapeutic strategies for different subtypes of adenomyosis: an initial single-center study in China. Int J Gynaecol Obstet. 2023; 161(3): 775-783. doi:10.1002/ijgo.14650 - 36Matsubara S, Kawaguchi R, Akinishi M, et al. Subtype I (intrinsic) adenomyosis is an independent risk factor for dienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis. Sci Rep. 2019; 9(1): 17654. doi:10.1038/s41598-019-54096-z - 37Chen CH, Lin YH, Lee CY, Shen H, Hsu YT, Wu PC. Long-term clinical outcomes of dienogest for perimenopausal women with symptomatic adenomyosis. Sci Rep. 2025; 15(1): 8174. doi:10.1038/s41598-025-93156-5 - 38Takagi H, Takakura M, Sasagawa T. Risk factors of heavy uterine bleeding in patients with endometriosis and adenomyosis treated with dienogest. Taiwan J Obstet Gynecol. 2023; 62(6): 852-857. doi:10.1016/j.tjog.2023.08.003 - 39Ono N, Asano R, Nagai K, Sugo Y, Nakamura T, Miyagi E. Evaluating the safety of dienogest in women with adenomyosis: a retrospective analysis. J Obstet Gynaecol Res. 2021; 47(4): 1433-1440. doi:10.1111/jog.14612 - 40Li L, Leng J, Jia S, Lang J. Treatment of symptomatic adenomyosis with the levonorgestrel-releasing intrauterine system. Int J Gynaecol Obstet. 2019; 146(3): 357-363. doi:10.1002/ijgo.12887 - 41Ishizawa C, Hirota Y, Iida R, et al. Levonorgestrel-releasing intrauterine system improves menorrhagia-related quality of life in patients with symptomatic Adenomyosis. Reprod Sci. 2023; 30(3): 966-973. doi:10.1007/s43032-022-01077-9 - 42Choudhury S, Jena SK, Mitra S, Padhy BM, Mohakud S. Comparison of efficacy between levonorgestrel intrauterine system and dienogest in adenomyosis: a randomized clinical trial. Ther Adv Reprod Health. 2024; 18:26334941241227401. doi:10.1177/26334941241227401 - 43Patil SS, Jadhav V, Pathak N. A study of the effect of the Levonorgestrel intrauterine system on the management of abnormal uterine bleeding. Cureus. 2025; 17(11):e96235. doi:10.7759/cureus.96235 - 44Zhang B, Shi J, Gu Z, et al. The role of different LNG-IUS therapies in the management of adenomyosis: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2025; 23(1):23. doi:10.1186/s12958-025-01349-4 - 45Pragash V, Khakhar A. Efficacy and outcomes of the hormone-releasing Levonorgestrel-intrauterine system for Adenomyosis treatment. Cureus. 2025; 17(11):e97669. doi:10.7759/cureus.97669 - 46Harada T, Ota I, Kitawaki J, et al. Real-world outcomes of the levonorgestrel-releasing intrauterine system for heavy menstrual bleeding or dysmenorrhea in Japanese patients: a prospective observational study (J-MIRAI). Contraception. 2022; 116: 22-28. doi:10.1016/j.contraception.2022.08.006 - 47Huang XW, Zeng XB, Luo XS, Shi BB, Xia WT, Zheng RR. Progressively optimized fixation method for levonorgestrel-releasing intrauterine device. Fertil Steril. 2025; 125: 380-382. doi:10.1016/j.fertnstert.2025.11.019 - 48Ribeiro F, Ferreira H. Novel minimally invasive surgical approaches to endometriosis and Adenomyosis: a comprehensive review. J Clin Med. 2024; 13(22):6844. doi:10.3390/jcm13226844 - 49Chong GO, Lee YH, Hong DG, Cho YL, Lee YS. Long-term efficacy of laparoscopic or robotic Adenomyomectomy with or without medical treatment for severely symptomatic Adenomyosis. Gynecol Obstet Investig. 2016; 81(4): 346-352. doi:10.1159/000441783 - 50Tan J, Moriarty S, Taskin O, et al. Reproductive outcomes after fertility-sparing surgery for focal and diffuse Adenomyosis: a systematic review. J Minim Invasive Gynecol. 2018; 25(4): 608-621. doi:10.1016/j.jmig.2017.12.020 - 51Athanasiou A, Fruscalzo A, Dedes I, et al. Advances in Adenomyosis treatment: high-intensity focused ultrasound, percutaneous microwave therapy, and radiofrequency ablation. J Clin Med. 2024; 13(19):5828. doi:10.3390/jcm13195828 - 52Hu S, Guo W, Chen S, Wu Z, Zhuang W, Yang J. Factors associated with dysmenorrhoea and menorrhagia improvement in patients with adenomyosis after uterine artery embolisation. J Obstet Gynaecol. 2024; 44(1):2372645. doi:10.1080/01443615.2024.2372645 - 53Cai Y, Sun Y, Xu F, et al. Effects of high-intensity focused ultrasound combined with levonorgestrel-releasing intrauterine system on patients with adenomyosis. Sci Rep. 2023; 13(1): 9903. doi:10.1038/s41598-023-37096-y - 54Lee YL, Bai YS, Yu MH, et al. Effectiveness of high-intensity focused ultrasound combined with gonadotropin-releasing hormone agonist or combined with levonorgestrel-releasing intrauterine system for adenomyosis: a systematic review and meta-analysis. Taiwan J Obstet Gynecol. 2024; 63(4): 492-499. doi:10.1016/j.tjog.2024.01.036 - 55Ota K, Takahashi T, Shiraishi S, Mizunuma H. Combination of microwave endometrial ablation and postoperative dienogest administration is effective for treating symptomatic adenomyosis. J Obstet Gynaecol Res. 2018; 44(9): 1787-1792. doi:10.1111/jog.13720 - 56Yang X, Zhang X, Lin B, Feng X, Aili A. Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis. Int J Hyperth. 2019; 36(1): 486-492. doi:10.1080/02656736.2019.1595179 - 57Huang Y, Yao L, Zhuo B. Individualized strategies and future perspectives of high-intensity focused ultrasound combined with pharmacological treatment for adenomyosis-associated infertility: a narrative review. Eur J Obstet Gynecol Reprod Biol. 2025; 315:114737. doi:10.1016/j.ejogrb.2025.114737 - 58Tang Y, Hu WH, Wang H, et al. Magnetic resonance imaging-based classification Systems for Informing Better Outcomes of Adenomyosis after ultrasound-guided high-intensity focused ultrasound ablating surgery. J Magn Reson Imaging. 2024; 59(5): 1787-1797. doi:10.1002/jmri.28943 - 59 2021 exceptional surveillance of heavy menstrual bleeding: assessment and management (NICE guideline NG88). National Institute for Health and Care Excellence (NICE). 2021. https://www.ncbi.nlm.nih.gov/books/NBK571008/ - 60Dason ES, Maxim M, Sanders A, et al. Guideline No. 437: diagnosis and Management of Adenomyosis. J Obstet Gynaecol Can. 2023; 45(6): 417-429.e1. doi:10.1016/j.jogc.2023.04.008 Article Metrics Total unique accesses to an article’s full text in HTML or PDF/ePDF format.More metric information Scite metrics Explore this article's citation statements on scite.ai Share QR Code Generating QR code QR code copied to clipboard! Something went wrong while generating your QR code. Please try again in a moment. If the issue persists, refresh the page or contact support. Export citation Unable to load citation data. Please try again in a moment. How to cite Elkins, L. J., & Spiegelman, M. (2021). pyUserCalc: A revised Jupyter notebook calculator for uranium-series disequilibria in basalts. Earth and Space Science, 8, e2020EA001619. https://doi.org/10.1029/2020EA001619 Download Citation If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click on download. This feature enables you to download the bibliographic information (also called citation data, header data, or metadata) for the articles on our site. Citation manager file format Use the dropdown list to choose how to format the bibliographic data you're harvesting. Several citation manager formats are available, including EndNote and BibTex. You can then copy the formatted citation (as displayed) or download it as file, to your device. If the RefWorks format is chosen, the 'Download' button will be replaced with an option to directly export to RefWorks